In head and neck squamous cell carcinoma (HNSCC), irrespective of PD-L1 expression status, immunotherapy with nivolumab and pembrolizumab is consented by FDA for the second-line treatment of recurrent and/or metastatic HNSCC [43]. Here, CD274 is linked to head and neck squamous cell carcinoma.